Eşti aici:Cytological And Anarchic Proliferation Of Cancer Mesothelioma

Cytological And Anarchic Proliferation Of Cancer Mesothelioma

An interesting study is called, "intrapulmonary localized fibrous tumor parenchyma called localized fibrous mesothelioma." This yous SA, SD Flynn -. Am J Clin Pathol. 1988 March; 89 (3): 365-9. Here is an excerpt:. "Abstract - This paper describes three cases of intrapulmonary fibroma histologically identical fibrous localized tumors of the pleura (localized fibrous mesothelioma) morphologically these tumors with uncontrolled proliferation of bland cytological cells spindles with different amounts of wool hyalinized collagen characterized separately. Included is widespread bronchioles and alveolar epithelium. Cell spindle lack expression of cytoplasmic keratin, s-100 protein, desmin, and epithelial membrane antigen, but are highly decorated for intracellular vimentin Text. clinical behavior, differential diagnosis and histogenesis of these lesions are discussed. "



mesothelial cells macrophagesDepartment of Internal Medicine, University of Texas Health Science Center at Tyler - S Shetty, A and S Kumar Idell: Another interesting study "Identification of new urokinase receptor mRNA binding protein in human cells mesothelioma adding the transcriptional regulation of mRNA urokinase receptor" called 75710, USA. Moth. mesothelial cell Differentiation (whatismesotheliomasymptoms.com). Biol. 03, 1997, 1075-1083, Vol 17, No. 3 American Society for Microbiology. Here is an excerpt: "Treatment of human pleural mesothelioma (MS-1) cells with phorbol myristate acetate (PMA) and the results of cycloheximide to 17 and 10 times and increases the expression of steady state urokinase plasminogen activator receptor (uPAR shown) mRNA. Transcriptional inhibition studies by actinomycin D, and four extension six times the half-life uPAR mRNA MS-1 treated with PMA and cycloheximide cells, respectively, suggesting that the gene expression uPAR comprises a post-transcriptional regulation mechanism. -Mobilitäts using gel shift assays UV crosslinking, we identified uPAR mRNA 50-kDa binding protein (uPAR mRNABp), which led to a 51-nucleotide bound selectively (s) a fragment of mRNA encoding corresponds uPAR. we examined the possibility that the 51-nt mRNA binding protein fragment of uPAR containing the communication requirements of stability. beta globin chimera / uPAR / beta globin mRNA, the binding group to the protein 51-nt otherwise may have beta-globin permanent destabilization of the mRNA. In contrast, the control chimeric beta-globin / uPAR / beta globin mRNA, containing a fragment of uPAR-coding region of the 51-nt, which They do not bind uPAR mRNABp not stable. Under the same conditions the binding of uPAR uPAR mRNA mRNABp was removed after treatment with cycloheximide and quickly downregulated PMA. These data suggest that the fragment-binding protein 51 nt mRNA uPAR may be involved in restoring and stabilizing mRNA messages uPAR induced cycloheximide. Our results demonstrate novel gene regulatory mechanism in which uPAR interact cis-elements in the 51-nt-encoding uPAR with mRNABp regulate uPAR stability messages. "

An interesting study is called, "Good symptom relief in palliative MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma" - Oxford journal Annals of Medicine OncologyVolume9, Issue 3 pp 269-273. - GW Middleton, IE Smith, SEA O'Brien, A. Norton, T. Hickish, K. Priest, L. Spencer and Ashley S. - Here is an excerpt: "Abstract - Objective: to evaluate the therapeutic effects of combination chemotherapy single malignant mesothelioma symptoms materials. and methods :. .. In the period from October 1986 to June 1997, 39 patients with unresectable malignant mesothelioma advanced stage were palliative MVP (mitomycin-C 8 mg / m six weeks to heal vinblastine 6 mg / 2 q 3 weeks and cisplatin 50 mg / m2 q third weeks) chemotherapy response and auxiliary objective results evaluated symptoms: Eight of 39 patients (20%) achieved an objective partial response with a median duration of nine months: only five patients, disease progression during chemotherapy had. Twenty-four of 39 (62%) had overall improvement of symptoms with a very good response to pain (79%). These benefits were independent of the state of fulfillment. the disappearance of symptoms was achieved in all patients who responded in both treatment cycles. There was no statistically significant difference in duration and frequency of symptoms in response to patients who achieved PR against X unchanged, and 60% of patients with X unchanged provide useful control symptoms, treatment was well with only four patients developed grade 3 leukopenia and nausea 3 three tolerated. Conclusion: The MVP is well tolerated therapy and its use in malignant mesothelioma provides a useful symptomatic benefit. These results should serve as a basis for further studies MVP in the treatment of mesothelioma symptom control as the primary endpoint.

We must all gratitude to these fine researchers. If you found any of these excerpts interesting, please read the study in its entirety.